Cargando…

Patient-derived models: Advanced tools for precision medicine in neuroblastoma

Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the...

Descripción completa

Detalles Bibliográficos
Autores principales: Aaltonen, Kristina, Radke, Katarzyna, Adamska, Aleksandra, Seger, Alexandra, Mañas, Adriana, Bexell, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910084/
https://www.ncbi.nlm.nih.gov/pubmed/36776363
http://dx.doi.org/10.3389/fonc.2022.1085270
_version_ 1784884713705439232
author Aaltonen, Kristina
Radke, Katarzyna
Adamska, Aleksandra
Seger, Alexandra
Mañas, Adriana
Bexell, Daniel
author_facet Aaltonen, Kristina
Radke, Katarzyna
Adamska, Aleksandra
Seger, Alexandra
Mañas, Adriana
Bexell, Daniel
author_sort Aaltonen, Kristina
collection PubMed
description Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in vitro cultures. These models can be used to decipher mechanisms of metastasis and treatment resistance, for drug screening, and preclinical drug testing. Patient-derived neuroblastoma models may also provide useful information about clonal evolution, phenotypic plasticity, and cell states in relation to neuroblastoma progression. We summarize current opportunities for, but also barriers to, future model development and application. Integration of patient-derived models with patient data holds promise for the development of precision medicine treatment strategies for children with high-risk neuroblastoma.
format Online
Article
Text
id pubmed-9910084
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99100842023-02-10 Patient-derived models: Advanced tools for precision medicine in neuroblastoma Aaltonen, Kristina Radke, Katarzyna Adamska, Aleksandra Seger, Alexandra Mañas, Adriana Bexell, Daniel Front Oncol Oncology Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in vitro cultures. These models can be used to decipher mechanisms of metastasis and treatment resistance, for drug screening, and preclinical drug testing. Patient-derived neuroblastoma models may also provide useful information about clonal evolution, phenotypic plasticity, and cell states in relation to neuroblastoma progression. We summarize current opportunities for, but also barriers to, future model development and application. Integration of patient-derived models with patient data holds promise for the development of precision medicine treatment strategies for children with high-risk neuroblastoma. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9910084/ /pubmed/36776363 http://dx.doi.org/10.3389/fonc.2022.1085270 Text en Copyright © 2023 Aaltonen, Radke, Adamska, Seger, Mañas and Bexell https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Aaltonen, Kristina
Radke, Katarzyna
Adamska, Aleksandra
Seger, Alexandra
Mañas, Adriana
Bexell, Daniel
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
title Patient-derived models: Advanced tools for precision medicine in neuroblastoma
title_full Patient-derived models: Advanced tools for precision medicine in neuroblastoma
title_fullStr Patient-derived models: Advanced tools for precision medicine in neuroblastoma
title_full_unstemmed Patient-derived models: Advanced tools for precision medicine in neuroblastoma
title_short Patient-derived models: Advanced tools for precision medicine in neuroblastoma
title_sort patient-derived models: advanced tools for precision medicine in neuroblastoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910084/
https://www.ncbi.nlm.nih.gov/pubmed/36776363
http://dx.doi.org/10.3389/fonc.2022.1085270
work_keys_str_mv AT aaltonenkristina patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma
AT radkekatarzyna patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma
AT adamskaaleksandra patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma
AT segeralexandra patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma
AT manasadriana patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma
AT bexelldaniel patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma